Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
To be comfortable holding Revvity, you need to believe in a pivot from a slower-growing, capital-intensive instruments business toward higher-margin, software-led life sciences workflows and disciplined capital allocation. The upcoming Q2 2026 earnings call and any updates to the US$2.96–2.99 billion revenue outlook remain the key near-term catalysts, along with signs that AI-enabled Signals products can gain commercial traction. The new Signals for Startups program and expanded sustainability reporting probably do not move near-term numbers in a material way, but they do reinforce the narrative that Revvity wants to be embedded earlier in biotech R&D and align with institutional ESG expectations. Against a rich earnings multiple and modest revenue growth forecasts, the biggest risk is that execution on this software and AI story proves slower or lumpier than the market is currently pricing in.
However, one risk around execution and valuation deserves closer attention from investors. Despite retreating, Revvity's shares might still be trading 24% above their fair value. Discover the potential downside here.Two Simply Wall St Community fair value views cluster between US$117.13 and US$144.53, showing how far individual estimates can stretch. Set against Revvity’s premium earnings multiple and slower expected revenue growth, these differing opinions highlight why many readers look across several viewpoints before committing capital.
Explore 2 other fair value estimates on Revvity - why the stock might be worth as much as 31% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com